ReviewiLIVER2025
Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions.
Review in iLIVER, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Insights to Precision Therapeutics.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Research Progress on the Application of Radiomics and Deep Learning in Liver Fibrosis.Journal of imaging · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Artificial intelligence (AI) is increasingly integrated into hepatology, yet the existing evidence is fragmented. This scoping review systematically mapped clinical AI applications across hepatology, summarized validated outcomes, and highlighted implementation challenges and research priorities. Methods: Following the Arksey-O'Malley and Levac frameworks and reported in accordance with PRISMA-ScR, a systematic search of PubMed, Embase, Scopus, Web of Science, and IEEE Xplore (January 2018-July 2025), complemented by grey-literature screening, identified relevant studies. Two reviewers independently screened and extracted data. From 3214 records, 75 studies met inclusion criteria. (PROSPERO ID: CRD420251159117). Results: Most studies were retrospective and single-center. Imaging models achieved area-under-curve values of 0.80-0.95 for fibrosis staging, lesion detection, and volumetry, often comparable with expert radiologists. Digital-pathology algorithms enabled objective quantification of fibrosis and steatosis. Machine-learning tools improved prediction of disease progression, readmission, and mortality compared with conventional scores, while AI-based transplantation models enhanced donor-recipient matching and graft-survival forecasting. Natural-language-processing systems facilitated early complication detection from electronic health records. Common barriers included small datasets, limited external validation, and model interpretability concerns. Conclusions: AI demonstrates strong potential for diagnostic, prognostic, and workflow enhancement in hepatology. Its responsible translation requires multimodal data integration, explainable modeling, prospective and multicenter validation, and equity-focused deployment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.